The insider sales are routine director-level diversification and do not signal bearish conviction. The strong Q1 earnings and reaffirmed guidance support the current business trajectory. Monitor the AZSTARYS acquisition close and any post-close guidance update for the combined entity.
COLL drugs
COLL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $33.65entry
- T+1 · 6mo ago −0.09%α +0.56% · $33.62
- T+5 · 6mo ago +0.39%α −1.23% · $33.78
- T+20 · 5mo ago +2.97%α +1.39% · $34.65
- T+60 · 3mo ago −23.63%α −28.48% · $25.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days of the company reporting strong Q1 2026 earnings (revenue +9% YoY, JORNAY PM +36%). The sales are small relative to the $1.1B market cap (~0.04%) and are not clustered with C-suite insiders, making them routine diversification trades rather than informed selling. The earnings report reaffirmed full-year guidance and highlighted the pending AZSTARYS acquisition, which is expected to close in Q2 2026.
Key Financial Metrics
Key Facts
- Two directors sold a total of $485K in open-market shares over 4 days (May 11-13, 2026).
- Sales represent ~0.04% of Collegium's $1.1B market cap, immaterial.
- No C-suite insiders (CEO, CFO, etc.) sold shares in the cluster.
- Q1 2026 earnings (filed May 7) showed net revenue of $193.5M (+9% YoY) and JORNAY PM revenue of $38.9M (+36% YoY).
- Full-year 2026 guidance reaffirmed: Product Revenues $805-825M, Adjusted EBITDA $455-475M.
- Pending AZSTARYS acquisition for $650M cash expected to close in Q2 2026.
Financial Impact
Insider sales of $485K are trivial relative to $1.1B market cap, no material financial impact.
Risk Factors
- AZSTARYS acquisition integration risk and $650M cash outlay could pressure balance sheet.
- Pain portfolio revenue growth is modest (+4% YoY) and faces generic competition risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-COLL-1779135356733 |
Track record
24 reports on COLL
1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers